EdgarLookup

IMMERSION CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that IMMERSION CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
591.6%
Profit Margin
Net income ÷ revenue
5.8%
Return on Assets
Net income ÷ assets
1.82x
Debt-to-Equity
Total liabilities ÷ equity
+27.1%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Dec 31, 2018 $10.87M Feb 27, 2019
FY2018 Sep 30, 2018 $8.55M Feb 27, 2019
FY2018 Jun 30, 2018 $6.14M Feb 27, 2019
FY2018 Mar 31, 2018 $85.42M Feb 27, 2019
FY2018 Dec 31, 2017 $6.90M Feb 27, 2019
FY2018 Sep 30, 2017 $11.86M Feb 27, 2019
FY2018 Jun 30, 2017 $7.03M Feb 27, 2019
FY2018 Mar 31, 2017 $9.22M Feb 27, 2019
FY2017 Dec 31, 2016 $9.29M Feb 27, 2018
FY2017 Sep 30, 2016 $26.31M Feb 27, 2018

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $1.56B Mar 12, 2026
FY2025 Jan 31, 2025 $471.26M Mar 12, 2026
FY2025 Oct 31, 2024 $616.25M Mar 12, 2026
FY2025 Jul 31, 2024 $89.94M Mar 12, 2026
FY2025 Jun 30, 2024 $95.48M Mar 12, 2026
FY2025 Apr 30, 2024 $45.78M Mar 12, 2026
FY2025 Dec 31, 2023 $33.92M Mar 12, 2026
FY2023 Dec 31, 2022 $38.46M Mar 11, 2024
FY2022 Dec 31, 2021 $35.09M Feb 22, 2023
FY2021 Dec 31, 2020 $30.46M Feb 25, 2022

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2019 Dec 31, 2019 $11.41M Mar 6, 2020
FY2019 Sep 30, 2019 $10.56M Mar 6, 2020
FY2019 Jun 30, 2019 $8.70M Mar 6, 2020
FY2019 Mar 31, 2019 $5.11M Mar 6, 2020
FY2019 Dec 31, 2018 $10.84M Mar 6, 2020
FY2019 Sep 30, 2018 $8.49M Mar 6, 2020
FY2019 Jun 30, 2018 $6.05M Mar 6, 2020
FY2019 Mar 31, 2018 $85.38M Mar 6, 2020
FY2018 Dec 31, 2017 $6.86M Feb 27, 2019
FY2018 Sep 30, 2017 $11.80M Feb 27, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $64.28M Mar 12, 2026
FY2025 Jan 31, 2025 $24.06M Mar 12, 2026
FY2025 Oct 31, 2024 $30.80M Mar 12, 2026
FY2025 Jul 31, 2024 ($246.0K) Mar 12, 2026
FY2025 Jun 30, 2024 $26.45M Mar 12, 2026
FY2025 Apr 30, 2024 $17.78M Mar 12, 2026
FY2025 Dec 31, 2023 $33.98M Mar 12, 2026
FY2023 Dec 31, 2022 $30.66M Mar 11, 2024
FY2022 Dec 31, 2021 $12.48M Feb 22, 2023
FY2021 Dec 31, 2020 $5.40M Feb 25, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $118.02M Mar 12, 2026
FY2025 Jan 31, 2025 $35.24M Mar 12, 2026
FY2025 Oct 31, 2024 $70.43M Mar 12, 2026
FY2025 Jul 31, 2024 ($9.64M) Mar 12, 2026
FY2025 Jun 30, 2024 $22.62M Mar 12, 2026
FY2025 Apr 30, 2024 $16.03M Mar 12, 2026
FY2025 Dec 31, 2023 $17.93M Mar 12, 2026
FY2023 Dec 31, 2022 $24.42M Mar 11, 2024
FY2022 Dec 31, 2021 $17.78M Feb 22, 2023
FY2021 Dec 31, 2020 $2.22M Feb 25, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2023 Dec 31, 2023 $281.0K Mar 11, 2024
FY2023 Dec 31, 2022 $1.38M Mar 11, 2024
FY2022 Dec 31, 2021 $4.15M Feb 22, 2023
FY2021 Dec 31, 2020 $5.01M Feb 25, 2022
FY2020 Dec 31, 2019 $7.84M Mar 5, 2021
FY2019 Dec 31, 2018 $9.73M Mar 6, 2020
FY2019 Dec 31, 2017 $11.76M Mar 6, 2020
FY2018 Dec 31, 2016 $13.39M Feb 27, 2019
FY2017 Dec 31, 2015 $14.79M Feb 27, 2018
FY2016 Dec 31, 2014 $11.79M Mar 3, 2017

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 ($57.58M) Mar 12, 2026
FY2025 Jan 31, 2025 ($107.67M) Mar 12, 2026
FY2025 Oct 31, 2024 ($63.98M) Mar 12, 2026
FY2025 Jun 30, 2024 ($56.03M) Mar 12, 2026
FY2025 Apr 30, 2024 $31.60M Mar 12, 2026
FY2025 Dec 31, 2023 $20.60M Mar 12, 2026
FY2023 Dec 31, 2022 $40.15M Mar 11, 2024
FY2022 Dec 31, 2021 $17.45M Feb 22, 2023
FY2021 Dec 31, 2020 $22.0K Feb 25, 2022
FY2020 Dec 31, 2019 ($34.10M) Mar 5, 2021

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $11.24M Mar 12, 2026
FY2025 Jan 31, 2025 $8.13M Mar 12, 2026
FY2025 Oct 31, 2024 $5.59M Mar 12, 2026
FY2025 Jun 30, 2024 $928.0K Mar 12, 2026
FY2025 Apr 30, 2024 $0 Mar 12, 2026
FY2025 Dec 31, 2023 $0 Mar 12, 2026
FY2022 Dec 31, 2022 $30.0K Feb 22, 2023
FY2022 Dec 31, 2021 $335.0K Feb 22, 2023
FY2021 Dec 31, 2020 $47.0K Feb 25, 2022
FY2020 Dec 31, 2019 $150.0K Mar 5, 2021

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $1.10B Mar 12, 2026
FY2025 Jan 31, 2025 $1.44B Mar 12, 2026
FY2025 Oct 31, 2024 $1.36B Mar 12, 2026
FY2025 Jun 30, 2024 $1.23B Mar 12, 2026
FY2025 Dec 31, 2023 $215.73M Mar 12, 2026
FY2023 Dec 31, 2022 $190.11M Mar 11, 2024
FY2022 Dec 31, 2021 $175.52M Feb 22, 2023
FY2021 Dec 31, 2020 $96.13M Feb 25, 2022
FY2020 Dec 31, 2019 $124.85M Mar 5, 2021
FY2019 Dec 31, 2018 $146.00M Mar 6, 2020

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $543.58M Mar 12, 2026
FY2025 Jan 31, 2025 $849.97M Mar 12, 2026
FY2025 Oct 31, 2024 $876.60M Mar 12, 2026
FY2025 Jun 30, 2024 $819.93M Mar 12, 2026
FY2025 Dec 31, 2023 $32.63M Mar 12, 2026
FY2023 Dec 31, 2022 $32.41M Mar 11, 2024
FY2022 Dec 31, 2021 $34.23M Feb 22, 2023
FY2021 Dec 31, 2020 $32.15M Feb 25, 2022
FY2020 Dec 31, 2019 $41.09M Mar 5, 2021
FY2019 Dec 31, 2018 $46.34M Mar 6, 2020

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $298.13M Mar 12, 2026
FY2025 Jan 31, 2025 $317.95M Mar 12, 2026
FY2025 Oct 31, 2024 $305.50M Mar 12, 2026
FY2025 Jun 30, 2024 $273.40M Mar 12, 2026
FY2025 Dec 31, 2023 $183.10M Mar 12, 2026
FY2023 Dec 31, 2022 $157.70M Mar 11, 2024
FY2023 Dec 31, 2021 $141.30M Mar 11, 2024
FY2022 Dec 31, 2020 $63.98M Feb 22, 2023
FY2021 Dec 31, 2019 $83.76M Feb 25, 2022
FY2020 Dec 31, 2018 $99.66M Mar 5, 2021

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2023 $0 Mar 12, 2026

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $34.69M Mar 12, 2026
FY2025 Jan 31, 2025 $53.86M Mar 12, 2026
FY2025 Oct 31, 2024 $38.10M Mar 12, 2026
FY2025 Jun 30, 2024 $9.06M Mar 12, 2026
FY2025 Dec 31, 2023 ($36.04M) Mar 12, 2026
FY2023 Dec 31, 2022 ($70.02M) Mar 11, 2024
FY2022 Dec 31, 2021 ($100.68M) Feb 22, 2023
FY2021 Dec 31, 2020 ($113.16M) Feb 25, 2022
FY2020 Dec 31, 2019 ($118.57M) Mar 5, 2021
FY2019 Dec 31, 2018 ($98.52M) Mar 6, 2020

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $72.61M Mar 12, 2026
FY2025 Apr 30, 2024 $85.52M Mar 12, 2026
FY2025 Dec 31, 2023 $56.07M Mar 12, 2026
FY2023 Dec 31, 2022 $48.82M Mar 11, 2024
FY2022 Dec 31, 2021 $51.49M Feb 22, 2023
FY2021 Dec 31, 2020 $59.52M Feb 25, 2022
FY2020 Dec 31, 2019 $86.48M Mar 5, 2021
FY2019 Dec 31, 2018 $110.99M Mar 6, 2020
FY2018 Dec 31, 2017 $24.62M Feb 27, 2019
FY2018 Dec 31, 2016 $56.87M Feb 27, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $103.10M Mar 12, 2026

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 1 Mar 12, 2026
FY2025 Jan 31, 2025 0 Mar 12, 2026
FY2025 Oct 31, 2024 0 Mar 12, 2026
FY2025 Jul 31, 2024 0 Mar 12, 2026
FY2025 Jun 30, 2024 0 Mar 12, 2026
FY2025 Apr 30, 2024 0 Mar 12, 2026
FY2025 Dec 31, 2023 1 Mar 12, 2026
FY2023 Dec 31, 2022 0 Mar 11, 2024
FY2022 Dec 31, 2021 0 Feb 22, 2023
FY2021 Dec 31, 2020 0 Feb 25, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 1 Mar 12, 2026
FY2025 Jan 31, 2025 0 Mar 12, 2026
FY2025 Oct 31, 2024 0 Mar 12, 2026
FY2025 Jul 31, 2024 0 Mar 12, 2026
FY2025 Jun 30, 2024 0 Mar 12, 2026
FY2025 Apr 30, 2024 0 Mar 12, 2026
FY2025 Dec 31, 2023 1 Mar 12, 2026
FY2023 Dec 31, 2022 0 Mar 11, 2024
FY2022 Dec 31, 2021 0 Feb 22, 2023
FY2021 Dec 31, 2020 0 Feb 25, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 32.50M Mar 12, 2026
FY2025 Jan 31, 2025 32.40M Mar 12, 2026
FY2025 Oct 31, 2024 48.69M Mar 12, 2026
FY2025 Jun 30, 2024 31.96M Mar 12, 2026
FY2025 Dec 31, 2023 31.53M Mar 12, 2026
FY2023 Dec 31, 2022 32.25M Mar 11, 2024
FY2022 Dec 31, 2021 34.39M Feb 22, 2023
FY2021 Dec 31, 2020 27.02M Feb 25, 2022
FY2020 Dec 31, 2019 31.41M Mar 5, 2021
FY2019 Dec 31, 2018 30.83M Mar 6, 2020

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $12.85M Mar 12, 2026
FY2025 Jan 31, 2025 $11.34M Mar 12, 2026
FY2025 Oct 31, 2024 $3.04M Mar 12, 2026
FY2025 Jun 30, 2024 $2.99M Mar 12, 2026
FY2025 Apr 30, 2024 $2.99M Mar 12, 2026
FY2025 Dec 31, 2023 $7.41M Mar 12, 2026
FY2023 Dec 31, 2022 $0 Mar 11, 2024